Oncotype-DX can assess the chemotherapy benefit and risk of recurrence within 10 years after breast cancer surgery in HR-positive, HER2-negative, node-negative, or limited to 1-3 node-positive patients. The gene discussed is ERBB2; the disease is breast carcinoma.